Abraham S et al. J Am Coll Cardiol. Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19.

Ronen Arbel et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med.

Carlos K H Wong et al. Real-world effectiveness of early Molnupiravir or Nirmatrelvir–Ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis.

Sarju Ganatra et al. Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19. Clinical Infectious Diseases.

Ross SB et al. Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications. JAMA Netw Open. 

Wisniewski, M et al. Outcomes After SARS-CoV-2 Vaccination Among Children With a History of Multisystem Inflammatory Syndrome. 

Chandler, T et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms.

Lewnard, J et al. Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study. The Journal of Infectious Diseases.

Miwako Kobayashi, MD et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Weekly.

Willen, L et al. Infant Pneumococcal Carriage in Belgium Not Affected by COVID-19 Containment Measures. Front Cell Infect Microbiol. 

Christian Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms.